Literature DB >> 18418675

Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration.

Gwenn A Garden1, Albert R La Spada.   

Abstract

Spinocerebellar ataxia type 7 (SCA7) is unique among CAG/polyglutamine (polyQ) repeat diseases due to dramatic intergenerational instability in repeat length and an associated cone-rod dystrophy retinal degeneration phenotype. SCA7 is caused by a polyQ expansion in the protein ataxin-7. Like other neurodegenerative diseases caused by polyQ expansion mutations, the spectrum of clinical severity and disease progression worsens with increasing polyQ length. Several potential mechanisms for the molecular pathogenesis of polyQ-expanded ataxin-7 have been suggested. These include, but are not limited to, alteration of endogenous ataxin-7 function, abnormal processing and stability of polyQ ataxin-7, and alteration of transcriptional regulation via interaction of polyQ-expanded ataxin-7 with other transcriptional regulators. Ataxin-7's normal function as a transcription factor may contribute to the selective vulnerability of specific cellular populations in SCA7, and the resolution of the mechanistic basis of this pathogenic cascade is a major focus of SCA7 disease research. PolyQ-expanded ataxin-7 can cause non-cell autonomous neurodegeneration in cerebellar Purkinje cells. Advances in understanding SCA7's molecular basis have led to important insights into cell-type specific neurodegeneration. We expect that further study of ataxin-7 normal function, insights into the molecular basis of SCA7 neurodegeneration, and the development of therapeutic interventions for SCA7 will greatly influence related endeavors directed at other CAG/polyQ repeat diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18418675      PMCID: PMC4195584          DOI: 10.1007/s12311-008-0027-y

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  95 in total

1.  Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.

Authors:  F C Nucifora ; M Sasaki; M F Peters; H Huang; J K Cooper; M Yamada; H Takahashi; S Tsuji; J Troncoso; V L Dawson; T M Dawson; C A Ross
Journal:  Science       Date:  2001-03-23       Impact factor: 47.728

Review 2.  The mediator of RNA polymerase II.

Authors:  Erik Blazek; Gerhard Mittler; Michael Meisterernst
Journal:  Chromosoma       Date:  2005-02-03       Impact factor: 4.316

3.  Chronic intraventricular infusion of glial cell line-derived neurotrophic factor (GDNF) rescues some cerebellar Purkinje cells from heredodegeneration.

Authors:  D L Tolbert; M W Bradley; E G Tolod; I Torres-Aleman; B R Clark
Journal:  Exp Neurol       Date:  2001-08       Impact factor: 5.330

4.  Classification of the hereditary ataxias and paraplegias.

Authors:  A E Harding
Journal:  Lancet       Date:  1983-05-21       Impact factor: 79.321

5.  Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.

Authors:  Aaron B Bowman; Seung-Yun Yoo; Nico P Dantuma; Huda Y Zoghbi
Journal:  Hum Mol Genet       Date:  2005-01-20       Impact factor: 6.150

6.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

Authors:  R Luthi-Carter; A Strand; N L Peters; S M Solano; Z R Hollingsworth; A S Menon; A S Frey; B S Spektor; E B Penney; G Schilling; C A Ross; D R Borchelt; S J Tapscott; A B Young; J H Cha; J M Olson
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

7.  Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7.

Authors:  A R La Spada; Y H Fu; B L Sopher; R T Libby; X Wang; L Y Li; D D Einum; J Huang; D E Possin; A C Smith; R A Martinez; K L Koszdin; P M Treuting; C B Ware; J B Hurley; L J Ptácek; S Chen
Journal:  Neuron       Date:  2001-09-27       Impact factor: 17.173

8.  Molecular and clinical study of spinocerebellar ataxia type 7 in Chinese kindreds.

Authors:  W Gu; Y Wang; X Liu; B Zhou; Y Zhou; G Wang
Journal:  Arch Neurol       Date:  2000-10

9.  Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.

Authors:  Ivelisse Sánchez; Christian Mahlke; Junying Yuan
Journal:  Nature       Date:  2003-01-23       Impact factor: 49.962

10.  On an autosomal dominant form of retinal-cerebellar degeneration: an autopsy study of five patients in one family.

Authors:  J J Martin; N Van Regemorter; L Krols; J M Brucher; T de Barsy; H Szliwowski; P Evrard; C Ceuterick; M J Tassignon; H Smet-Dieleman
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

View more
  42 in total

1.  Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration.

Authors:  Stephanie A Furrer; Mathini S Mohanachandran; Sarah M Waldherr; Christopher Chang; Vincent A Damian; Bryce L Sopher; Gwenn A Garden; Albert R La Spada
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

Review 2.  Intercellular (mis)communication in neurodegenerative disease.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

3.  Clinical and molecular effect on offspring of a marriage of consanguineous spinocerebellar ataxia type 7 mutation carriers: a family case report.

Authors:  Jonathan J Magaña; Yessica S Tapia-Guerrero; Luis Velázquez-Pérez; Tania Cruz-Mariño; Cesar M Cerecedo-Zapata; Rocío Gómez; Nadia M Murillo-Melo; Rigoberto González-Piña; Oscar Hernández-Hernández; Bulmaro Cisneros
Journal:  Int J Clin Exp Med       Date:  2014-12-15

4.  Genetic variation in ataxia gene ATXN7 influences cerebellar grey matter volume in healthy adults.

Authors:  Charlotte D C C van der Heijden; Mark Rijpkema; Alejandro Arias-Vásquez; Marina Hakobjan; Hans Scheffer; Guillen Fernandez; Barbara Franke; Bart P van de Warrenburg
Journal:  Cerebellum       Date:  2013-06       Impact factor: 3.847

Review 5.  Genetic syndromes caused by mutations in epigenetic genes.

Authors:  María Berdasco; Manel Esteller
Journal:  Hum Genet       Date:  2013-01-31       Impact factor: 4.132

6.  A comprehensive clinical and genetic study of a large Mexican population with spinocerebellar ataxia type 7.

Authors:  L Velázquez-Pérez; C M Cerecedo-Zapata; O Hernández-Hernández; E Martínez-Cruz; Y S Tapia-Guerrero; R González-Piña; J Salas-Vargas; R Rodríguez-Labrada; R Gurrola-Betancourth; N Leyva-García; B Cisneros; J J Magaña
Journal:  Neurogenetics       Date:  2014-10-16       Impact factor: 2.660

7.  Spinocerebellar ataxia Type 7: clinical and genetic study of a new Moroccan family (case report).

Authors:  Fatima Zahra Bouzid; Maria Mansouri; Chaikhy Abdelaziz; Nisrine Louhab; Sablonniere Bernard; Isabelle Strubi-Vuillaume; Kenza Dafir; Nisrine Aboussair
Journal:  Pan Afr Med J       Date:  2021-02-12

8.  Ataxin-7 associates with microtubules and stabilizes the cytoskeletal network.

Authors:  Yoko Nakamura; Kazuhiko Tagawa; Tsutomu Oka; Toshikazu Sasabe; Hikaru Ito; Hiroki Shiwaku; Albert R La Spada; Hitoshi Okazawa
Journal:  Hum Mol Genet       Date:  2011-11-18       Impact factor: 6.150

9.  Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7.

Authors:  Pavitra S Ramachandran; Ryan L Boudreau; Kellie A Schaefer; Albert R La Spada; Beverly L Davidson
Journal:  Mol Ther       Date:  2014-06-16       Impact factor: 11.454

10.  Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype.

Authors:  Janine Scholefield; L Jacquie Greenberg; Marc S Weinberg; Patrick B Arbuthnot; Amr Abdelgany; Matthew J A Wood
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.